This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects (ULDS)

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01135446
First received: May 27, 2010
Last updated: October 14, 2016
Last verified: October 2016
  Purpose
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.

Condition Intervention Phase
Type 2 Diabetes Drug: dapagliflozin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect [ Time Frame: 24 hours after dosing ]

Secondary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 24 hours after dosing ]
  • Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics [ Time Frame: 2 days after dosing ]

Enrollment: 35
Study Start Date: May 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: dapagliflozin (0.001 mg)
Cohort 1
Drug: dapagliflozin
Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
Other Name: BMS-512148
Experimental: dapagliflozin (0.01 mg)
Cohort 2
Drug: dapagliflozin
Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
Other Name: BMS-512148
Experimental: dapagliflozin (0.1 mg)
Cohort 3
Drug: dapagliflozin
Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
Other Name: BMS-512148
Experimental: dapagliflozin (0.3 mg)
Cohort 4
Drug: dapagliflozin
Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
Other Name: BMS-512148
Experimental: dapagliflozin (1 mg)
Cohort 5
Drug: dapagliflozin
Tablets, Oral, 1 mg, once on Day 1 only, 2 days
Other Name: BMS-512148
Experimental: dapagliflozin (2.5 mg)
Cohort 6
Drug: dapagliflozin
Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
Other Name: BMS-512148

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and women
  • WOCBP who are using acceptable method of contraception
  • Women who are not nursing

Exclusion Criteria:

  • History of GI disease
  • Any GI surgery that could impact study drug absorption
  • Glucosuria at screening or Day -2
  • Abnormal liver function tests (ALT, AST or total bilirubin > 10% above ULN)
  • History of current or recurrent UTI
  • History of Diabetes Mellitus
  • History of chronic or recurrent vulvovaginal mycotic infections
  • Estimated creatinine clearance (ClCr) < 80 mL/min using Cockroft-Gault formula
  • History of allergy to SGLT2 inhibitors or related compounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01135446

Locations
United States, Texas
Ppd Development, Lp
Austin, Texas, United States, 78744
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01135446     History of Changes
Other Study ID Numbers: MB102-088
Study First Received: May 27, 2010
Last Updated: October 14, 2016

ClinicalTrials.gov processed this record on August 18, 2017